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Abstract  
Background: A proficiency testing scheme was set up for the DRUID (Driving under the influence of 
Drugs, Alcohol and Medicines) research project, funded by the European Commission, in which oral 
fluid is analysed by eleven laboratories. A common collection and analysis methodology is used: 
Statsure Saliva Sampler is used for collection and LC-MS/MS or GC-MS confirmation analysis of 22 
substances is performed on all samples. Despite internal validation and quality control samples, 
external quality assessment is still necessary to further increase comparability of results. Four rounds 
of proficiency testing (PT) were organized between March 2008 and September 2009. 
Methods: Qualitative results were evaluated using sensitivity and specificity. Quantitative results were 
evaluated using z-scores and the standard deviation of Horwitz. 
Results: Specificity was above 99% in each round, sensitivity per analyte varied between 81.7 and 
100%, 20 out of 22 analytes had a sensitivity above 90%. The percentage of satisfactory z-scores 
increased from 79.4% to 89.2%. This trend was seen for all drug classes, except zopiclone. Results 
were discussed with participating laboratories and problems were addressed.  
Conclusions: Because of these corrective actions, DRUID laboratories have a lower variation in results 
than previously published PT schemes in oral fluid.  
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1. Introduction 
The use of oral fluid as a matrix for detection of drugs of abuse has increased continuously over the 
last ten years.[1] More and more information has become available on the pharmacokinetics of both 
licit and illicit drugs[2], leading to a better understanding of the relationship between concentrations 
found in oral fluid and the effects of the drugs. Because of its non-invasive, supervised and easy 
collection, policy makers are also interested in oral fluid as an alternative matrix to blood and urine for 
detection of impaired drivers. Several countries worldwide (Australia, France, Belgium) have already 
implemented legislation based on oral fluid. 
DRUID (Driving Under the Influence of Drugs, Alcohol and Medicines) is an integrated research 
project funded by the European Commission that deals with licit and illicit drugs in driving. Oral fluid is 
collected in this study for several purposes: it is taken from randomly selected drivers in order to 
calculate the prevalence of psychoactive substances in the general European driving population and 
to calculate odds ratios to be injured in an accident after taking these substances. Also, all 
experimental studies in DRUID are collecting oral fluid for comparison with concentrations in other 
matrices. Finally, oral fluid is taken as reference samples from patients in pain clinics, coffeeshops and 
centers for treatment of drug addiction to test rapid on-site testing devices for screening of drugs of 
abuse in oral fluid. 
In total over 40,000 samples will be collected using the Statsure saliva sampler™ (Statsure Diagnostic 
Systems, Framingham, MA, USA). This collection device was chosen from ten devices based on ease 
of collection, stability and recovery of analytes and collection volume.[3] All samples have to be 
analyzed for the presence of a ‘core list’ of 22 substances containing both licit and illicit drugs. 
Minimum analytical cut-offs were defined for all analytes.[4] (Table 1) Samples are analyzed by eleven 
countries across Europe. Since results of the different laboratories will be combined for calculations 
and most labs had to develop new methods for this project, interlaboratory quality control (i.e. 
proficiency testing) is necessary. The aim of the proficiency-testing scheme was to ensure that the 
quality and comparability of the results from all laboratories. In the past, similar programs have been 
organized: UKNEQAS (United Kingdom National External Quality Assessment Scheme) was the first 
to publish interlaboratory results[5], followed by ORALVEQ[6, 7] and the ROSITA-2 project.[8] None of 
these existing programs could however be used for the DRUID project since tests had to be adapted 
to the DRUID core list of analytes and cut-offs. 
2. Materials and methods 
Drug standards used in the preparation of oral fluid PT samples were purchased as powders from 
Sigma-Aldrich  (St. Louis, Missouri, USA) or as methanolic solutions from Cerilliant (Round Rock, 
Texas, USA).  
Oral fluid PT samples were prepared in a synthetic oral fluid matrix developed at RTI International. 
The synthetic oral fluid consisted of salts and proteins found in human oral fluid with no preservatives 
added. Each sample was formulated to contain 3 to 5 analytes. The 22 analytes, target concentration 
ranges and number of sample spikes for each analyte are listed in Table 1. 1.5 mL of neat oral fluid 
was dispensed into a 4 mL silanized amber vial (Supelco St. Louis, Missouri, USA), capped with a 
Teflon-lined cap (Supelco) and frozen until shipment. Samples for each survey year were prepared in 
a single production. Ten sample types were prepared in December 2007 for the two 2008 surveys 
(round 1 and 2) and ten new sample types were prepared in January 2009 for the two 2009 surveys 
round 3 and 4). Each sample vial was labeled with a unique identification number.  
PT samples were packaged in cardboard boxes with styrofoam containers and dry ice (for countries 
able to accept dry ice and ice packs for those countries barring dry ice) in plastic buckets and shipped 
using express delivery to each of the participating laboratories. A total of 4 sets with 5 samples in each 
set were shipped between March 2008 and September 2009.  
Laboratories were instructed to add 1 mL of the neat oral fluid sample to a StatSure collection device.  
The 1 mL of neat PT oral fluid was added directly to the buffer in the collection tube.  The neat oral 
fluid was not to be added to the swab pad nor was the swab pad to be added to the buffer in the 
collection tube. Analytes were screened, identified and quantified using a mass spectroscopy-based 
technique. Reported analyte concentrations were corrected for dilutions to provide the concentration 
for the neat oral fluid shipped to the laboratory. Samples were expected to be tested and electronically 
reported to RTI within 10 working days after receipt. Results were reported back to each participating 
lab anonymously, but with identification to the DRUID coordinator to allow the latter to make corrective 
actions. 
Qualitative results were evaluated using sensitivity and specificity. Sensitivity is defined as the number 
of analytes correctly reported positive divided by the total number of analytes spiked in the samples. 
Specificity is defined as the number of analytes correctly reported negative divided by the total number 
of core list analytes not spiked in the samples. 
Quantification was evaluated using the standard deviation according to Horwitz (SDHOR). This 
parameter is used in the IUPAC international Harmonized Protocol for proficiency testing and is 
independent of the results of the laboratories as a group. Z-scores were calculated using SDHOR:  
 
 
    VC = variation coefficient (%) 
    C = analyte concentration (kg/L) 
 
 
3. Results 
Eight laboratories reported results in the first round, three laboratories did not yet report because 
method development and validation were still being performed. In the second to fourth round, all 
eleven laboratories reported results. Not all laboratories reported results for ethanol, since in some 
countries ethanol concentration for each volunteer was already known based on breathalyzer results 
from standard police procedure and hence analysis was not mandatory. 
Nine laboratories performed the analysis using LC-MS/MS (liquid chromatography tandem mass 
spectrometry), two laboratories used GC-MS (gas chromatography mass spectrometry). Ethanol 
analyses were performed with either headspace gas chromatography or enzymatic methods. 
Average coefficients of variation (CV) were below 20% for 4 out of 22 analytes, 13 others had an 
average CV between 20 and 30%. Specificity was above 99% for all analytes; sensitivity varied 
between 81.7 and 100%, 20 out of 22 analytes had sensitivity above 90%. (Table 1). 
In Figure 1, it can be seen that quantification improved over the rounds as well: laboratories with a 
satisfactory z-score (absolute value lower than 2) increased from 79.4% over 86.8% and 88.7% to 
89.2%. Z-scores were also combined for the following groups: opiates (including methadone), 
benzodiazepines, amphetamines, cocaine (and benzoylecgonine), ethanol, delta-9-
tetrahydrocannabinol (THC) and z-drugs (zolpidem and zopiclone). False negatives were mostly 
attributable to z-drugs, benzodiazepines and THC. Laboratories scored the lowest for quantification of 
amphetamines and z-drugs. For cocaine and opiates, almost no false negatives were observed while 
satisfactory quantification was achieved in respectively 89.4% and 92.5% of cases. Quantification of 
THC was satisfactory in 89.2% of cases. For ethanol, there were no false negatives results and 
satisfactory quantification was obtained in 95.8% of cases. 
Results per substance were subdivided per testing round. These demonstrate that specificity for 
amphetamines, cocaine, opiates and THC improved over time, with no false negatives (except one FN 
for 6-acetylmorphine) remaining in round 3 and 4. (Figure 2 and Figure 3) For benzodiazepines as 
well, specificity improved over time, except in round 3 where one lab experienced temporary hardware 
problems. The Z-drugs remained the most difficult group during all rounds, although some 
improvement can be observed in round 4. (Figure 4) The majority of problems with the z-drugs were 
encountered with zopiclone: 12 out of 14 false negatives are for zopiclone, only 2 for zolpidem. 
Overall, scores for quantification remained approximately the same over time, except for z-drugs and 
cocaine where a clear improvement was seen in round 4. 
In testing rounds 1 and 4, several labs reported benzoylecgonine present in samples where only 
cocaine was spiked but no benzoylecgonine. After consultation with participating laboratories this 
problem could be explained by hydrolysis of cocaine during extraction and low extraction yields for 
benzoylecgonine or by pre-analytical hydrolysis, either in sample preparation at the manufacture or 
during shipment. Since the exact source of the benzoylecgonine could not be pointed out, and the 
presence of variable amounts of benzoylecgonine is to be expected in samples containing cocaine, 
these reported values were not scored as false positives. 
 
4. Discussion 
Prior to the DRUID project, most participating laboratories did not analyze oral fluid on a routine basis 
and therefore had to develop LC-MS/MS or GC-MS methods specifically for this project. In the first 
round of proficiency testing, most laboratories were therefore still in the process of development and 
validation or had only recently completed this, explaining the lower scores in the first rounds. After 
each round, results were discussed in meetings with the participating laboratories and the DRUID 
coordinator (based on Z-scores), problems were identified and solutions sought for. Thanks to this 
extensive distribution of knowledge between the participating laboratories, the quality of analyses 
increased significantly over time, leading to a last round with low false negative (0.9%) and false 
positive (0.4%) results. Satisfactory quantification was achieved in almost 90% of cases. 
Zopiclone remained the most difficult compound for qualitative analysis. It is known that 
cyclopyrrolones can hydrolyse under different conditions to 2-amino-5-chloropyridine, which could 
explain the analytical problems.[9, 10] Moreover, when the participating laboratories developed their 
confirmation methods, deuterated zopiclone was not yet available to be used as internal standard. 
Amphetamines proved to be the most difficult class of drugs for quantitative analyses. 
Laboratories were not allowed to analyze specimens until approval from the coordinator was obtained, 
which was based on internal validation and proficiency testing results. This was decided in order to 
further improve quality of analysis of specimens from DRUID volunteers. 
Analysis using coefficients of variation shows that the DRUID laboratories have a lower variance in 
results than the participants of previously published proficiency testing programs for the majority of 
analytes: in this program the average CV was lower than 30% for 77.3% of analytes, while this was 
the case for only 46.1 % of analytes in UKNEQAS and none of the analytes in ORALVEQ.[5, 6]  
It should be noted that two key variables in oral fluid analysis are not considered in the program: 
sample volume and recovery from the device. However for analysis of all real samples, variation is 
minimized since weighing of the sample volume is mandatory and recovery from the device is 
reproducible because of the use of the same collection and extraction device. 
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  Table 1: number of samples spiked with target analytes, concentration ranges and DRUID cut-offs. 
Sensitivity and specificity, minimum, maximum and average coefficient of variation. 
CV 
Analyte 
DRUID 
cutoff 
(ng/mL) 
Sample 
concentration 
range 
(ng/mL) 
Number of 
Sample 
Challenges 
Sens  Spec  
Average Min Max Outliers$ 
6-acetylmorphine 5 8-15 4 93.9% 100% 27.4% 21.7% 34.8%  
Alprazolam 1 2-6 4 92.7% 100% 26.0% 17.4% 41.2% 2 
Amphetamine 25 50-100 4 92.7% 100% 22.9% 12.3% 42.3%  
Benzoylecgonine 10 20-80 5 98.1% 100% 31.2% 25.5% 36.4% 2 
Clonazepam 1 2-2 2 100% 100% 27.4% 21.3% 33.5%  
Cocaine 10 20-80 6 96.7% 99.3% 19.1% 13.1% 24.5%  
Codeine 20 25-60 3 100% 100% 35.3% 32.1% 41.1%  
Diazepam 5 10-15 2 100% 99.5% 22.2% 17.2% 27.2%  
Ethanol 0.1 g/L 0.2-0.8 g/L 8 100% 100% 11.2% 6.5% 18.9% 2 
Flunitrazepam 1 2-6 2 81.8% 99.5% 28.8% 19.7% 37.9%  
Lorazepam 1 2-3 2 90.9% 100% 20.4% 18.1% 22.7% 1 
MDMA 25 50-75 2 100% 100% 35.9% 31.2% 40.7%  
MDA 25 75-75 2 100% 100% 30.8% 26.9% 34.7%  
MDEA 25 75-75 2 100% 100% 28.9% 27.8% 30.0% 1 
Methadone 20 30-40 2 100% 99.5% 18.5% 18.3% 18.7%  
Methamphetamine 25 40-75 3 94.7% 100% 28.7% 28.1% 29.0% 1 
Morphine 20 25-60 4 100% 100% 28.1% 13.5% 46.6% 1 
Nordiazepam 1 2-5 2 95.5% 99.5% 18.3% 16.2% 20.4%  
Oxazepam 5 10-10 2 94.7% 99.5% 27.4% 17.0% 37.7%  
THC 1 3-10 8 93.9% 100% 25.7% 13.7% 35.2% 1 
Zolpidem 10 15-40 3 93.3% 100% 22.2% 16.2% 32.6%  
Zopiclone 10 15-40 6 81.7% 99.3% 34.5% 15.2% 65.1% 2 
$ outlier defined as value with more than 100% deviation from mean 
	  	  
Figure 1: z-scores and false negatives for each testing round and per class of drugs (rounds 
combined) 
 Figure 2: z-scores and false negatives for amphetamines (left) and cocaine (+benzoylecgonine) (right) 
	  Figure 3: z-scores and false negatives for opiates (left; no opiates present in round 2) and THC (right) 
 
Figure 4: z-scores and false negatives for benzodiazepines (left), zopiclone and zolpidem (right) 
 
Reference List 
 
 (1)  Pil K, Verstraete A. Current Developments in Drug Testing in Oral Fluid. Ther Drug Monit 2008 
April;30(2):196-202. 
 (2)  Drummer OH. Review: Pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int 2005 June 
10;150(2-3):133-42. 
 (3)  Langel K, Engblom C, Pehrsson A, Gunnar T, Ariniemi K, Lillsunde P. Drug testing in oral fluid-
evaluation of sample collection devices. J Anal Toxicol 2008 July;32(6):393-401. 
 (4)  Pil K, Raes E, Verstraete A. The toxicological challenges in the European research project 
DRUID. Forensic Science International Supplement Series 2009; 1: 29-32. 
 (5)  Clarke J, Wilson JF. Proficiency testing (external quality assessment) of drug detection in oral 
fluid. Forensic Science International 2005 June 10;150(2-3):161-4. 
 (6)  Ventura M, Ventura R, Pichini S et al. ORALVEQ: external quality assessment scheme of drugs 
of abuse in oral fluid: results obtained in the first round performed in 2007. Forensic Sci Int 2008 
November 20;182(1-3):35-40. 
 (7)  Ventura M, Pichini S, Ventura R et al. Stability of drugs of abuse in oral fluid collection devices 
with purpose of external quality assessment schemes. Ther Drug Monit 2009 April;31(2):277-80. 
 (8)  Wille SM, Raes E, Lillsunde P et al. Relationship between oral fluid and blood concentrations of 
drugs of abuse in drivers suspected of driving under the influence of drugs. Ther Drug Monit 
2009 August;31(4):511-9. 
 (9)  Fernandez C, Gimenez F, Mayrargue J, Thuillier A, Farinotti R. Degradation and racemization of 
zopiclone enantiomers in plasma and partially aqueous solutions. Chirality 1995;7(4):267-71. 
 (10)  Mannaert E, Tytgat J, Daenens P. Detection of 2-amino-5-chloropyridine in urine as a parameter 
of zopiclone (Imovane) intake using HPLC with diode array detection. J Anal Toxicol 1997 
May;21(3):208-12. 
 
 
	  
